Free Trial

BioRestorative Therapies Q3 2023 Earnings Report

BioRestorative Therapies logo
$2.12 +0.15 (+7.61%)
As of 01/21/2025 04:00 PM Eastern

BioRestorative Therapies EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

BioRestorative Therapies Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
$0.03 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

BioRestorative Therapies Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

BioRestorative Therapies Earnings Headlines

Roth MKM Remains a Buy on BioRestorative Therapies (BRTX)
Trump currency shock imminent
Trump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launched a $1.9 trillion move against the Fed. What comes next could have dramatic consequences.
See More BioRestorative Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioRestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioRestorative Therapies and other key companies, straight to your email.

About BioRestorative Therapies

BioRestorative Therapies (OTCMKTS:BRTX) engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.

View BioRestorative Therapies Profile

More Earnings Resources from MarketBeat